Centre Hospitalier Universitaire de Grenoble

Low-Dose Deferasirox Shows Promise in Treating Anemia in Low-Risk MDS

- The LODEFI phase 2 trial demonstrated that low-dose deferasirox induced transfusion independence in nearly half of patients with low-risk myelodysplastic syndrome (MDS). - A stricter definition of transfusion independence showed that over two-thirds of patients achieved transfusion independence at 12 months with deferasirox. - The study suggests low-dose deferasirox could be a potential treatment for anemia in MDS patients who are refractory or relapsing to erythropoietin-stimulating agents (ESAs). - Low-dose deferasirox was well-tolerated, with mainly grade 1 to 3 adverse effects, supporting its use in this patient population.